Medivolve

Medivolve is a public healthcare technology and services company focused on technology-enabled care delivery rather than drug development. The company became known for building U.S. retail patient-care and specimen collection operations through its Collection Sites subsidiary and for offering diagnostic testing and telehealth-related services, initially with a strong emphasis on COVID-19 testing. Over time, Medivolve described its strategy as evolving toward a more data-driven, SaaS-enabled health-tech and management-services model intended to improve access, workflow, and patient engagement. It is not a traditional biotech or pharmaceutical developer and does not appear to have a therapeutic drug pipeline. The company has traded publicly in Canada and the U.S. and has undergone management changes and strategic repositioning as pandemic-related testing demand declined.